KT
Pasithea Therapeutics Corp.
KTTAW · NASDAQ
$0.00 +0.00% (+$0.00)
1M -53.95%
Market Cap $26.0K
P/E Ratio -
Div. Yield -
ROE 42.35%
Bulios Fair Price
$0.01
150.0% upside
Current Price
$0.004
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KTTAW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.00x
EV/EBITDA N/A
P/S N/A
Growth
76 /100
Growing Book val. growth 9.12%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 42.35%
ROA 10.23%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 26.25x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
24 /100
Unstable EPS volatility 53.16%
Profitable years 0
Beta 0.29x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KTTAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Tiago Reis Marques
Employees
5
Headquarters
Miami Beach
Upcoming events
02 DEC
Earnings
Upcoming earnings report